This announcement is a separate document:
*ST龙津：关于2023年年报问询函的回复公告
Kunming Longjin Pharmaceutical: Notice of Response to the 2023 Annual Report Inquiry Letter
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Risk Disclaimer
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Got it
Related Stocks Related Stocks
Latest
19:46
The armed factions supported by the USA and Turkey have not reached a ceasefire agreement.
19:46
Tesla rose 3% before the market opens. Mizuho Securities upgraded the company's rating.
TSLA+6.14%
19:45
Pfizer: Expected revenue in 2025 is between 61 billion and 64 billion USD, with an estimate of 63.23 billion USD.
PFE-1.29%
Statement
This page is machine-translated. Futubull tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.